Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568706 · ClinicalTrials.gov registry record · Phase 2
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
A Phase 2 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT05568706 is a Phase 2 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 186 participants.
The verdict
NCT05568706, a Phase 2 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
Interventions
- DRUG Placebo
- DRUG EDP-938
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2022-11-29 |
| Est. Completion | 2025-06-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05568706
The ClinicalTrials.gov registry entry for NCT05568706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05568706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05568706 about?
NCT05568706 is a clinical study titled "A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.". This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
What is the current status of trial NCT05568706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2022-11-29. Estimated completion is 2025-06-23.
What interventions are being tested in trial NCT05568706?
The interventions under investigation include: Placebo (DRUG), EDP-938 (DRUG).
Who is sponsoring clinical trial NCT05568706?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.